Alexander disease |
Brain of a 4-year-old boy with Alexander disease showing macroencephaly and periventricular leukomalacia (note brownish discoloration around the cerebral ventricles)
|
Classification and external resources |
ICD-10 |
E75.2 |
ICD-9 |
331.89 |
OMIM |
203450 137780 137780 203450 |
MeSH |
D038261 |
GeneReviews |
|
Alexander disease, also known as fibrinoid leukodystrophy, is a progressive and fatal neurodegenerative disease. It is a rare genetic disorder and mostly affects infants and children, causing developmental delay and changes in physical characteristics.[1][2][3]
Contents
- 1 Cause
- 2 Clinical features
- 3 Pathology
- 4 Diagnosis
- 5 Occurrence and prevalence
- 6 Treatment
- 7 Prognosis
- 8 See also
- 9 References
- 10 External links
Cause
Alexander disease is a genetic disorder affecting the midbrain and cerebellum of the central nervous system. It is caused by mutations in the gene for glial fibrillary acidic protein (GFAP)[4][5][6] that maps to chromosome 17q21. It is inherited in an autosomal dominant manner, such that the child of a parent with the disease has a 50% chance of inheriting the condition, if the parent is heterozygotic. However, most cases arise de novo as the result of sporadic mutations.[2]
Alexander disease belongs to leukodystrophies, a group of diseases that affect the growth or development of the myelin sheath. The destruction of white matter in the brain is accompanied by the formation of fibrous, eosinophilic deposits known as Rosenthal fibers.[2][3][7]Rosenthal fibers appear not to be present in healthy people,[3][8] but occur in specific diseases, like some forms of cancer.[3][8] The Rosenthal fibers found in Alexander disease do not share the distribution or concentration of other diseases and disorders.[3]
Clinical features
Delays in development of some physical, psychological and behavioral skills; progressive enlargement of the head (macrocephaly), seizures, spasticity, in some cases also hydrocephalus, idiopathic intracranial hypertension, dementia.[2]
Pathology
Alexander disease causes the gradual loss of bodily functions and the ability to talk. It also causes an overload of long chain fatty acids in the brain which the destroy the myelin sheath. The cause of Alexander disease is a mutation in the gene encoding glial fibrillary acidic protein.[2][3][4][5][9]
A CT scan shows:
- decreased density of white matter
- frontal lobe predominance
- +/- dilated lateral ventricles
Diagnosis
It is possible to detect the signs of Alexander disease with magnetic resonance imaging (MRI), which looks for specific changes in the brain that may be tell-tale signs for the disease.[10][11] It is even possible to detect adult-onset Alexander disease with MRI.[9] Alexander disease may also be revealed by genetic testing for the known cause of Alexander disease.[12][13] A rough diagnosis may also be made through revealing of clinical symptoms including, enlarged head size, along with radiological studies, and negative tests for other leukodystrophies.[8]
Occurrence and prevalence
Its occurrence is very rare. The infantile form from birth to 2 years of age.[6] The average duration of the infantile form of the illness is usually about 3 years. Onset of the juvenile form presents between two and twelve years of age.[6] Duration of this form is in most cases about 6 years. The adult form from twelve years and older.[6] In younger patients, seizures, megalencephaly, developmental delay, and spasticity are usually present. Neonatal onset is also reported.[14] Onset in adults is least frequent. In older patients, bulbar or pseudobulbar symptoms and spasticity predominate. Symptoms of the adult form may also resemble multiple sclerosis.[2]
There are no more than 500 reported cases.[2]
Treatment
There is currently no cure, or standard procedure taken for treatment.[2][3] A bone marrow transplant has been attempted on a child, but did not cause the patient's condition to improve.[15][16]
Prognosis
The prognosis is generally poor. With early onset, death usually occurs within 10 years from the onset of symptoms. Usually, the later the disease occurs, the slower its course is.[2][3]
See also
- The Myelin Project
- The Stennis Foundation
References
- ^ "MUTATION KEY TO ALEXANDER DISEASE" - United Press International
- ^ a b c d e f g h i GeneReviews/NCBI/NIH/UW entry on Alexander disease
- ^ a b c d e f g h alexander_disease at NINDS
- ^ a b Li R, Messing A, Goldman JE, Brenner M (2002). "GFAP mutations in Alexander disease". Int. J. Dev. Neurosci. 20 (3-5): 259–68. doi:10.1016/s0736-5748(02)00019-9. PMID 12175861.
- ^ a b Quinlan RA, Brenner M, Goldman JE, Messing A (June 2007). "GFAP and its role in Alexander disease". Exp. Cell Res. 313 (10): 2077–87. doi:10.1016/j.yexcr.2007.04.004. PMC 2702672. PMID 17498694.
- ^ a b c d Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE (April 2012). "Alexander disease". J. Neurosci. 32 (15): 5017–23. doi:10.1523/JNEUROSCI.5384-11.2012. PMC 3336214. PMID 22496548.
- ^ "Cause of brain disease found" -BBC News
- ^ a b c http://www.ulf.org/types/Alexander.html
- ^ a b Farina L, Pareyson D, Minati L et al. (June 2008). "Can MR imaging diagnose adult-onset Alexander disease?". AJNR Am J Neuroradiol 29 (6): 1190–6. doi:10.3174/ajnr.A1060. PMID 18388212.
- ^ Labauge P (June 2009). "Magnetic resonance findings in leucodystrophies and MS". Int MS J 16 (2): 47–56. PMID 19671368.
- ^ van der Knaap MS, Naidu S, Breiter SN et al. (March 2001). "Alexander disease: diagnosis with MR imaging". AJNR Am J Neuroradiol 22 (3): 541–52. PMID 11237983.
- ^ Johnson AB (2002). "Alexander disease: a review and the gene". Int. J. Dev. Neurosci. 20 (3-5): 391–4. doi:10.1016/S0736-5748(02)00045-X. PMID 12175878.
- ^ Sawaishi Y (August 2009). "Review of Alexander disease: beyond the classical concept of leukodystrophy". Brain Dev. 31 (7): 493–8. doi:10.1016/j.braindev.2009.03.006. PMID 19386454.
- ^ Singh N, Bixby C, Etienne D, Tubbs RS, Loukas M (December 2012). "Alexander's disease: reassessment of a neonatal form". Childs Nerv Syst 28 (12): 2029–31. doi:10.1007/s00381-012-1868-8. PMID 22890470.
- ^ Staba MJ, Goldman S, Johnson FL, Huttenlocher PR (August 1997). "Allogeneic bone marrow transplantation for Alexander's disease". Bone Marrow Transplant. 20 (3): 247–9. doi:10.1038/sj.bmt.1700871. PMID 9257894.
- ^ Messing A, LaPash Daniels CM, Hagemann TL (October 2010). "Strategies for treatment in Alexander disease". Neurotherapeutics 7 (4): 507–15. doi:10.1016/j.nurt.2010.05.013. PMC 2948554. PMID 20880512.
External links
- OMIM entries on Alexander disease
Cytoskeletal defects
|
|
Microfilaments |
Myofilament |
Actin |
- Hypertrophic cardiomyopathy 11
- Dilated cardiomyopathy 1AA
- DFNA20
- Nemaline myopathy 3
|
|
Myosin |
- Elejalde syndrome
- Hypertrophic cardiomyopathy 1, 8, 10
- Usher syndrome 1B
- Freeman–Sheldon syndrome
- DFN A3, 4, 11, 17, 22; B2, 30, 37, 48
- May-Hegglin anomaly
|
|
Troponin |
- Hypertrophic cardiomyopathy 7, 2
- Nemaline myopathy 4, 5
|
|
Tropomyosin |
- Hypertrophic cardiomyopathy 3
- Nemaline myopathy 1
|
|
Titin |
- Hypertrophic cardiomyopathy 9
|
|
|
Other |
- Fibrillin
- Marfan syndrome
- Weill-Marchesani syndrome
- Filamin
- FG syndrome 2
- Boomerang dysplasia
- Larsen syndrome
- Terminal osseous dysplasia with pigmentary defects
|
|
|
IF |
1/2 |
- Keratinopathy (keratosis, keratoderma, hyperkeratosis): KRT1
- Striate palmoplantar keratoderma 3
- Epidermolytic hyperkeratosis
- IHCM
- KRT2E (Ichthyosis bullosa of Siemens)
- KRT3 (Meesmann juvenile epithelial corneal dystrophy)
- KRT4 (White sponge nevus)
- KRT5 (Epidermolysis bullosa simplex)
- KRT8 (Familial cirrhosis)
- KRT10 (Epidermolytic hyperkeratosis)
- KRT12 (Meesmann juvenile epithelial corneal dystrophy)
- KRT13 (White sponge nevus)
- KRT14 (Epidermolysis bullosa simplex)
- KRT17 (Steatocystoma multiplex)
- KRT18 (Familial cirrhosis)
- KRT81/KRT83/KRT86 (Monilethrix)
- Naegeli–Franceschetti–Jadassohn syndrome
- Reticular pigmented anomaly of the flexures
|
|
3 |
- Desmin: Desmin-related myofibrillar myopathy
- Dilated cardiomyopathy 1I
- Peripherin: Amyotrophic lateral sclerosis
|
|
4 |
- Neurofilament: Parkinson's disease
- Charcot–Marie–Tooth disease 1F, 2E
- Amyotrophic lateral sclerosis
|
|
5 |
- Laminopathy: LMNA
- Mandibuloacral dysplasia
- Dunnigan Familial partial lipodystrophy
- Emery-Dreifuss muscular dystrophy 2
- Limb-girdle muscular dystrophy 1B
- Charcot–Marie–Tooth disease 2B1
- LMNB
- Barraquer–Simons syndrome
- LEMD3
- Buschke–Ollendorff syndrome
- Osteopoikilosis
- LBR
- Pelger-Huet anomaly
- Hydrops-ectopic calcification-moth-eaten skeletal dysplasia
|
|
|
Microtubules |
Kinesin |
- Charcot–Marie–Tooth disease 2A
- Hereditary spastic paraplegia 10
|
|
Dynein |
- Primary ciliary dyskinesia
- Short rib-polydactyly syndrome 3
- Asphyxiating thoracic dysplasia 3
|
|
Other |
- Tauopathy
- Cavernous venous malformation
|
|
|
Membrane |
- Spectrin: Spinocerebellar ataxia 5
- Hereditary spherocytosis 2, 3
- Hereditary elliptocytosis 2, 3
Ankyrin: Long QT syndrome 4
- Hereditary spherocytosis 1
|
|
Catenin |
- APC
- Gardner's syndrome
- Familial adenomatous polyposis
- plakoglobin (Naxos syndrome)
- GAN (Giant axonal neuropathy)
|
|
Other |
- desmoplakin: Striate palmoplantar keratoderma 2
- Carvajal syndrome
- Arrhythmogenic right ventricular dysplasia 8
- plectin: Epidermolysis bullosa simplex with muscular dystrophy
- Epidermolysis bullosa simplex of Ogna
- plakophilin: Skin fragility syndrome
- Arrhythmogenic right ventricular dysplasia 9
- centrosome: PCNT (Microcephalic osteodysplastic primordial dwarfism type II)
|
|
See also: cytoskeletal proteins
Index of cells
|
|
Description |
- Structure
- Organelles
- peroxisome
- cytoskeleton
- centrosome
- epithelia
- cilia
- mitochondria
- Membranes
- Membrane transport
- ion channels
- vesicular transport
- solute carrier
- ABC transporters
- ATPase
- oxidoreduction-driven
|
|
Disease |
- Structural
- peroxisome
- cytoskeleton
- cilia
- mitochondria
- nucleus
- scleroprotein
- Membrane
- channelopathy
- solute carrier
- ATPase
- ABC transporters
- other
- extracellular ligands
- cell surface receptors
- intracellular signalling
- Vesicular transport
- Pore-forming toxins
|
|
|